Should I buy or sell Allakos stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares. View ALLK analyst ratings or view top-rated stocks .

What is Allakos' stock price target for 2024?

5 Wall Street analysts have issued 1-year price objectives for Allakos' shares. Their ALLK share price targets range from $1.00 to $3.00. On average, they anticipate the company's stock price to reach $1.83 in the next twelve months. This suggests a possible upside of 74.6% from the stock's current price. View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts .

How have ALLK shares performed in 2024?

Allakos' stock was trading at $2.73 at the beginning of 2024. Since then, ALLK stock has decreased by 61.5% and is now trading at $1.05. View the best growth stocks for 2024 here .

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ALLK earnings forecast .

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.18.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV) , Advanced Micro Devices (AMD) , Pfizer (PFE) , Agios Pharmaceuticals (AGIO) , Biohaven (BHVN) , bluebird bio (BLUE) , Eastman Chemical (EMN) , Heron Therapeutics (HRTX) , TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS) .

When did Allakos IPO?

Allakos (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALLK

Allakos (ALLK) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free ALLK Stock Alerts

$1.05

-0.01 (-0.94%)

(As of 10:46 AM ET)

Compare

Today's Range: $1.05
▼
$1.09
50-Day Range: $1.05
▼
$1.64
52-Week Range: $1.00
▼
$5.64

Volume: 51,038 shs
Average Volume: 1.30 million shs
Market Capitalization: $92.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.83

Get Allakos alerts:

Allakos MarketRank™ Stock Analysis

Analyst Rating: Hold
2.20 Rating Score
Upside/Downside: 74.6% Upside
$1.83 Price Target
Short Interest: Healthy
6.33% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.86
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.16) to ($0.70) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.08 out of 5 stars

Medical Sector

160th out of 918 stocks

Pharmaceutical Preparations Industry

58th out of 424 stocks

3.1

Analyst's Opinion

Consensus Rating
Allakos has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Allakos has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.33% of the outstanding shares of Allakos have been sold short.
Short Interest Ratio / Days to Cover
Allakos has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Allakos has recently decreased by 0.71%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Allakos does not currently pay a dividend.
Dividend Growth
Allakos does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Allakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Allakos is -0.86.

0.6

News and Social Media Coverage

Search Interest
Only 1 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
2 people have added Allakos to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allakos insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.07% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Allakos are expected to grow in the coming year, from ($1.16) to ($0.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allakos is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allakos is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Allakos has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Allakos Stock (NASDAQ:ALLK)

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

ALLK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALLK Stock News Headlines

April 11, 2024 | americanbankingnews.com

Allakos (NASDAQ:ALLK) Stock Price Down 3.3%

April 9, 2024 | investorplace.com

3 Biotech Stocks to Dump Before They Go to Zero

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 19, 2024 | markets.businessinsider.com

Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program

March 16, 2024 | finance.yahoo.com

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

March 15, 2024 | markets.businessinsider.com

Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments

March 15, 2024 | markets.businessinsider.com

Buy Rating Maintained for Century Therapeutics with Increased Price Target Amid Promising Trials and Strong Financials

March 15, 2024 | markets.businessinsider.com

TD Cowen Remains a Hold on Allakos (ALLK)

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 14, 2024 | investorplace.com

ALLK Stock Earnings: Allakos Misses EPS for Q4 2023

March 14, 2024 | globenewswire.com

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | finanznachrichten.de

Allakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

February 26, 2024 | globenewswire.com

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

February 17, 2024 | finance.yahoo.com

ALLK Sep 2024 2.000 call

February 17, 2024 | finance.yahoo.com

ALLK Sep 2024 2.500 call

February 17, 2024 | finance.yahoo.com

ALLK Mar 2024 1.500 call

February 12, 2024 | finanznachrichten.de

Allakos Inc.: Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

February 12, 2024 | finance.yahoo.com

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

January 28, 2024 | stockhouse.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

January 18, 2024 | finance.yahoo.com

Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks

January 17, 2024 | realmoney.thestreet.com

Allakos price target lowered by 50c at Barclays, here's why

January 17, 2024 | msn.com

Allakos extends losses as analysts downgrade on Phase 2 setback

January 16, 2024 | realmoney.thestreet.com

Allakos just downgraded at Cantor Fitzgerald, here's why

January 16, 2024 | realmoney.thestreet.com

Allakos just downgraded at LifeSci Capital, here's why

January 16, 2024 | finance.yahoo.com

Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?

January 16, 2024 | investorplace.com

Why Is Allakos (ALLK) Stock Down 57% Today?

January 16, 2024 | marketwatch.com

Allakos to Cut Workforce by Half Amid Results from Lirentelimab Trials

See More Headlines

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALLK
CUSIP: N/A
CIK: 1564824
Web: www.allakos.com
Phone: (650) 597-5002
Fax: N/A
Employees: 131
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.83
High Stock Price Target: $3.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +73.0%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-185,700,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -80.23%
Return on Assets: -62.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.92
Quick Ratio: 4.92

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.93 per share
Price / Book: 0.55

Miscellaneous

Outstanding Shares: 87,870,000
Free Float: 63,208,000
Market Cap: $93.14 million
Optionable: Optionable
Beta: 0.82

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Robert Alexander Ph.D. (Age 54)
CEO & Director
Comp: $1.46M
Dr. Adam L. Tomasi Ph.D. (Age 54)
President
Comp: $1.11M
Mr. Baird Radford III (Age 54)
Chief Financial Officer
Comp: $708.26k
Ms. Mary Cromwell Ph.D.
Chief Technical Officer
Dr. Chin Lee M.D. (Age 53)
M.P.H., Chief Medical Officer
Mr. Alan Chang
Director of Medical Affairs & Data Analytics

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ALLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Allakos stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings or view top-rated stocks.
What is Allakos' stock price target for 2024?: 5 Wall Street analysts have issued 1-year price objectives for Allakos' shares. Their ALLK share price targets range from $1.00 to $3.00. On average, they anticipate the company's stock price to reach $1.83 in the next twelve months. This suggests a possible upside of 74.6% from the stock's current price.
View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts.
How have ALLK shares performed in 2024?: Allakos' stock was trading at $2.73 at the beginning of 2024. Since then, ALLK stock has decreased by 61.5% and is now trading at $1.05.
View the best growth stocks for 2024 here.
When is Allakos' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ALLK earnings forecast.

How were Allakos' earnings last quarter?: Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.18.
What other stocks do shareholders of Allakos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).
When did Allakos IPO?: Allakos (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.
How do I buy shares of Allakos?: Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLK) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allakos (ALLK) Stock Price, News & Analysis

Allakos MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Allakos Stock (NASDAQ:ALLK)

ALLK Stock Price History

ALLK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ALLK Stock Analysis - Frequently Asked Questions

Overall MarketRank^™